Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Product Pipeline Our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and Ebola virus (EBOV). We also have additional preclinical stage programs, including the Middle East Respiratory Syndrome coronavirus (MERS). Corporate Overview Novavax is headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Gaithersburg, US
443 (est)
Novavax was founded in 1987 and is headquartered in Gaithersburg, US

Novavax Locations

Gaithersburg, US
Uppsala, SE
Rockville, US

Novavax Metrics

Novavax Summary

Market capitalization

$372 M

Closing share price

Novavax's current market capitalization is $372 M.

Novavax Financials

Novavax's revenue is $36.3 M in FY, 2015 which is 18.24% increase from the previous period.
FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015


$343 K$14.7 M$22.1 M$20.9 M$30.7 M$36.3 M

Operating income

$-83.7 M$-157 M

Net Income

$-82.9 M$-157 M

Operating cash flow

$-87.1 M$60.8 M

    Novavax Market Value History

    Novavax Online Presence

    Novavax News

    Novavax Company Life